Gaurav D. Shah
Chief Executive Officer at ROCKET PHARMACEUTICALS, INC.
Net worth: 28 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Southwell | M | 63 |
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 10 years |
| Kinnari Patel | M | 46 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 8 years |
| Jonathan Schwartz | M | 60 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 8 years |
| John Militello | M | 50 | 6 years | |
| Pedro Granadillo | M | 77 | 6 years | |
| Fady Malik | M | 59 | 2 years | |
| Gayatri R. Rao | M | - | 6 years | |
| R. Woods | M | 57 | 1 years | |
| Martin Wilson | M | 47 | 3 years | |
| Carsten Boess | M | 57 | 8 years | |
| Margareta Elisabeth Björk | M | 63 | 4 years | |
| Mark White | M | 57 | 1 years | |
| Naveen Yalamanchi | M | 47 | 6 years | |
| Gotham Makker | M | 50 | 6 years | |
| Raj Prabhakar | M | 50 | 7 years | |
| Alessandro A. Piol | M | 67 |
The Trustees of Columbia University in The City of New York
| 15 years |
| Carlos Martin | M | - | - | |
| Samantha Vieira | F | - |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 years |
| Isabel Carmona | F | - | 3 years | |
| Kevin Giordano | M | - | 3 years | |
| Douglas Fambrough | M | 55 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 years |
| Rod Wong | M | 47 | 6 years | |
| Ami Miron | M | - |
The Trustees of Columbia University in The City of New York
| 15 years |
| Gordana Vunjak-Novakovic | M | 75 |
The Trustees of Columbia University in The City of New York
| 13 years |
| Mayo Pujols | M | 55 | 2 years | |
| Stephen Yoo | M | 46 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 years |
| Brooks Rahmer | M | - | - | |
| Dina Chaya | M | 52 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 3 years |
| Siddhartha Mukherjee | M | - |
The Trustees of Columbia University in The City of New York
| 15 years |
| Bali Muralidhar | M | 44 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian Batchelder | M | - | - | |
| Mayur Kasetty | M | - | 4 years | |
| Kareem Elsirafy | M | - |
The Trustees of Columbia University in The City of New York
| 8 years |
| Jan Lundberg | M | 70 | 8 years | |
| Joseph Thome | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Bo Wen | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Julian M. Richers | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Andrew D. Goldsmith | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Qiong Hai | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Claudine Prowse | M | - | 3 years | |
| Katherine Lin | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Yang Li | M | 41 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Jacob Ma-Weaver | M | 37 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Deirdre O’Donnell | F | - | - | |
| Dario Constantine | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Amrom Obstfeld | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Samuel Zhang | M | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | 4 years |
| Teresa Fazio | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Chris Ho | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Jeffrey A. Winton | M | - | 3 years | |
| Lina Fan | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Alistair James Meadows | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Bryan Christopher Hays | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Malindi N. Davies | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Amy Duffuor | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Ben Dahl | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Joel Camacho | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Cassidy Leventhal | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Zachary Sadow | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Troy Langford | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Cheng Chen | M | 38 |
The Trustees of Columbia University in The City of New York
| 1 years |
| Hillel Gontownik | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Allan Kang | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Jay Sullivan | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Elizabeth Crowe | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Nalin Tejavibulya | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Carter Caldwell | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Eliot Sackler | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Aditya Naganath | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Iani Alecsiu | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Jonathan Chen | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Ensieh Sarrami | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Tanay Jaipuria | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Dimitri Tahal | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Stanley Chen | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Amanda Stewart | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Cynthia M. Campo | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Kerem Tuzcuoglu | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Tanvi Gupta | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Zachary T. Calinoff | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Laurent Vasilescu | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Matthew Johnston | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Paul Corcoran | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Cristiano Amoruso | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Daniel Brillman | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| David Oscar Silverman | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Sean Morgan | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Isidore Smart | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Zachariah Reitano | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Sonya Chandra | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| David Rogovic | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Samer Samman | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Kareem Afifi | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Mark McCormick | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Chun-Yai Wang | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Matthew Joseph Gladstone | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Martin Lehr | M | 40 |
The Trustees of Columbia University in The City of New York
| 1 years |
| Megan Johnston Rand | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Lisa Thomas | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Mark Jenner | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 95 | 95.00% |
| Switzerland | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gaurav D. Shah
- Personal Network